Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
This case report (n=3) documents the first academic instances of olfactory improvement after psychedelic use. The study also discusses potential mechanisms, such as serotonergic effects, neuroplasticity, and anti-inflammatory effects, suggesting further research into psychedelics for olfactory dysfunction.
Authors
- Brian Barnett
Published
Abstract
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is limited. A growing body of online media claims that individuals have noticed improvement in anosmia and microsmia following classic psychedelic use. We report what we believe to be the first three cases recorded in the academic literature of improvement in olfactory impairment after psychedelic use. In the first case, a man who developed microsmia after a respiratory infection experienced improvement in smell after the use of 6 g of psilocybin containing mushrooms. In the second case, a woman with anosmia since childhood reported olfactory improvement after ingestion of 100 µg of lysergic acid diethylamide (LSD). In the third case, a woman with COVID-19-related anosmia reported olfactory improvement after microdosing 0.1 g of psilocybin mushrooms three times. Following a discussion of these cases, we explore potential mechanisms for psychedelic-facilitated improvement in olfactory impairment, including serotonergic effects, increased neuroplasticity, and anti-inflammatory effects. Given the need for novel treatments for olfactory dysfunction, increasing reports describing improvement in these conditions following psychedelic use and potential biological plausibility, we believe that the possible therapeutic benefits of psychedelics for these conditions deserve further investigation.
Research Summary of 'Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD'
Introduction
Olfactory dysfunction (OD), including anosmia (loss of smell) and microsmia (reduced smell), is associated with reduced quality of life across mood, safety, social engagement, and appetite. Common causes include sinonasal disease, trauma, and post-infectious injury; recent attention has focused on post-infectious OD because of the frequency and persistence of smell loss following COVID-19 infection. Existing treatments for post-infectious OD are limited: olfactory training has some supporting randomised evidence but modest benefit, while pharmacological and procedural options (topical/oral steroids, antibiotics, alpha-lipoic acid, stellate ganglion block, surgery) lack consistent efficacy for sensorineural forms of OD. Kovacevich and colleagues report what they describe as the first three cases in the medical literature of subjective or objective improvement in anosmia/microsmia following naturalistic use of classic psychedelics (psilocybin and LSD). The authors note that social and traditional media have suggested similar improvements and argue biological plausibility via serotonergic effects, enhanced neuroplasticity, and anti-inflammatory actions of classic psychedelics. The paper aims to present these three cases, document available objective testing where present, and explore potential mechanisms to motivate further formal investigation.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Author
- APA Citation
Kovacevich, A., Weleff, J., Claytor, B., & Barnett, B. S. (2023). Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. Journal of Psychoactive Drugs, 55(5), 672-679. https://doi.org/10.1080/02791072.2023.2253538
References (20)
Papers cited by this study that are also in Blossom
Ferris, J. A., Nutt, D. J. · Drug Science Policy and Law (2020)
Barnett, B. S., Sweat, N. W., Hendricks, P. S. · Drug Science Policy and Law (2023)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)
Show all 20 referencesShow fewer
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Inserra, A., De Gregorio, D., Gobbi, G. · Pharmacological Reviews (2021)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)
Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.